ORMP has been on a crazy bull run. This past month it has run 433%. Since its peak from 2 weaks ago, ORMP has retraced 50% of its' move and is showing promise of going on another run after breaking its' pennant
formation. During the pennant
declined, and then spiked on the brake out. This move is targeting anywhere from $35-45. In two days, January 29, ORMP's CEO
is going to announce the results of its' phase 2a testing for their new insulin drug. This could be the catalyst that sends this stock soaring.